India-based drugmakers must enhance manufacturing standards to address quality concerns impacting pharmaceutical exports. Amid rising scrutiny, the government is incentivizing upgrades to improve compliance and maintain global dominance in generics.
..
India-based drugmakers must enhance manufacturing standards to address quality concerns impacting pharmaceutical exports. Amid rising scrutiny, the government is incentivizing upgrades to improve compliance and maintain global dominance in generics.
Key View
India-based drugmakers will need to invest in improving manufacturing standards to meet rising pressures on drug quality to protect pharmaceutical exports.
India will continue to be a dominant force in global generic drug manufacturing and remain the primary supplier of generics in the US, but the industry continues to face scrutiny over quality control issues which will impact the approval rate of new drugs.
Rising cost-containment measures across key developed markets, such as the US and the EU, will create new prospects for India-based generic drug manufacturers.
India-based drugmakers will need to invest in improving…